Clincial Study Patient Recruitment and Site Engagement

Large B-Cell Lymphoma

Stark Raving Branding and Digital Marketing

A Clinical Study of an Investigational (CAR) T-cell Therapy for Large B-Cell Lymphoma

SponsorKite Pharma


ClientPRA Health Sciences


IndicationB-Cell Lymphoma


MaterialsPatient Outreach

 Patient Education

 Site Staff Materials

 Referring Physician

 Patient Retention

High-risk large B-cell lymphoma (LBCL) has poor outcomes with standard first-line chemoimmunotherapy. This phase 2, multicenter, single-arm clinical study we evaluated axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, as part of first-line treatment in 40 patients with high-risk LBCL. The primary objective was evaluate complete response rate (CRR). Secondary objectives were to evaluate objective response rate (ORR), duration of response (DOR), event-free survival (EFS), progression-free survival (PFS), overall survival (OS), assessment of safety, central nervous system (CNS) relapse and blood levels of CAR T cells and cytokines.

Stark Raving Branding and Digital Marketing

Let's talk about your next project
To discuss an upcoming project or to learn more about our services, please contact us.

Be sure you complete all fields. Thank you!